molindone (Moban, Lindone)
Jump to navigation
Jump to search
Introduction
Tradename: Moban.
Indications
symptomatic management of psychotic disorder
Contraindications
Caution:
- cardiovascular disease
- seizure disorder
Dosage
- start 25 mg PO TID
- adjust in 3-4 days as needed
- start elderly on lower dose
- max 225 mg/day
- doses of 400 mg/day have been used
Tabs: 5, 10, 25, 50, 100 mg.
Liquid: 20 mg/mL.
Pharmacokinetics
- rapidly & completely absorbed from the GI tract
- rapidly metabolized in the liver to inactive metabolites
- < 3% excreted unchanged in the urine
elimination via liver
elimination via kidney
Adverse effects
- common (> 10%)
- less common (1-10%)
- depression, change in menstrual cycle, breast swelling
- uncommon (< 1%)
- tachycardia, arrhythmias, sedation, drowsiness, restlessness, anxiety, seizures, altered temperature regulation, neuroleptic malignant syndrome, hyperpigmentation, pruritus, rash, galactorrhea, gynecomastia, weight gain, dry mouth, agranulocytosis*, leukopenia#, retinal pigmentation, photosensitivity
- other
- low sedation, anticholinergic & orthostatic hypotensive effects
- extrapyramidal symptoms (moderate)
- neuroleptic malignant syndrome (rare)
- QT prolongation
- direct myocardial suppression
* agranulocytosis is more common in women between 4th & 10th week of therapy
# leukopenia generally occurs with large doses for prolonged periods
Drug interactions
- see chlorpromazine
- molindone tablets contain CaSO4 & may inhibit absorption of:
- drug interaction(s) of antipsychotics & dopamine receptor agonists
- drug interaction(s) of antipsycotics with benzodiazepines
Mechanism of action
- intermediate potency antipsychotic agent
- relatively selective domapine D2 receptor antagonist
- see chlorpromazine
More general terms
Additional terms
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
- ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998